Chlorpropamide
Chlorpropamide
Contact Us

We are here to help in anything you need. Please use our online system or send an email to .

Chlorpropamide

Inquiry
Catalog Number PR94202
CAS 94-20-2
Description Chlorpropamide is an N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification. It has a role as a hypoglycemic agent and an insulin secretagogue.
Synonyms Diabinese
IUPAC Name 1-(4-chlorophenyl)sulfonyl-3-propylurea
Molecular Weight 276.74
Molecular Formula C10H13ClN2O3S
InChI RKWGIWYCVPQPMF-UHFFFAOYSA-N
InChI Key InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)
Drug Categories Alimentary Tract and Metabolism; Amides; Benzene Derivatives; Benzenesulfonamides; Blood Glucose Lowering Agents; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Drugs that are Mainly Renally Excreted; Drugs Used in Diabetes; Genito Urinary System and Sex Hormones; Gynecological Antiinfectives and Antiseptics; Hypoglycemia-Associated Agents; Insulin Secretagogues; OAT1/SLC22A6 inhibitors; Oral Hypoglycemics; Sulfonamides; Sulfones; Sulfonylureas; Sulfur Compounds
Drug Interactions Abacavir-Chlorpropamide may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abatacept-The metabolism of Chlorpropamide can be increased when combined with Abatacept.
Abrocitinib-The metabolism of Abrocitinib can be decreased when combined with Chlorpropamide.
Acamprosate-The excretion of Acamprosate can be decreased when combined with Chlorpropamide.
Acarbose-The risk or severity of hypoglycemia can be increased when Acarbose is combined with Chlorpropamide.
Isomeric SMILES CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl
Type Small Molecule
Therapeutic Category Antidiabetics
Pharmacology

Indications

Chlorpropamide is indicated for the management of non-insulin-dependent diabetes mellitus (NIDDM). It is intended for use in conjunction with a structured diet and regular exercise regimen to effectively control blood glucose levels in affected individuals.

Pharmacodynamics

Chlorpropamide belongs to the class of second-generation sulfonylurea antidiabetic agents. It functions by lowering blood glucose levels in patients diagnosed with type II diabetes mellitus, primarily when combined with dietary management strategies. Notably, chlorpropamide exhibits twice the potency of glipizide, another second-generation sulfonylurea, thereby providing a significant hypoglycemic effect.

Absorption

Upon administration, chlorpropamide is efficiently absorbed from the gastrointestinal tract. Peak plasma concentrations are typically observed within 2 to 4 hours, while its onset of action occurs approximately one hour after oral intake. The drug achieves its maximal effect within 3 to 6 hours post-administration, making it a rapidly acting oral antidiabetic option.

Metabolism

Chlorpropamide undergoes extensive metabolism, with up to 80% of the administered dose likely processed by the liver. The metabolic pathway includes the conversion to multiple compounds, specifically 2-hydroxylchlorpropamide (2-OH CPA), p-chlorobenzenesulfonylurea (CBSU), 3-hydroxylchlorpropamide (3-OH CPA), and p-chlorobenzenesulfonamide (CBSA). Notably, CBSA may also form through decomposition in the urine. The potential hypoglycemic effects of these metabolites remain undetermined.

Mechanism of Action

Chlorpropamide functions by interacting with ATP-sensitive potassium channels located on the surface of pancreatic β-cells. This interaction decreases the conductance of potassium ions, leading to membrane depolarization. As a result of this depolarization, voltage-sensitive calcium channels open, facilitating an influx of calcium ions. The increase in intracellular calcium concentration subsequently triggers the exocytosis of insulin from the β-cells.

It should be noted that our service is only used for research, not for clinical use.